Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with Reduced vs Intensive Consolidation in Ph+ ALL
NCT05026229Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of dasatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Percentage of Participants with Measurable Residual Disease Positivity up to 36 months and Percentage of Participants with Complete Remission up to 36 months. Status: unknown.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05026229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026229.